SIETES :: 91969 citas

Resultados de la búsqueda por POLÍTICAS SANITARIAS REFINAR BÚSQUEDA

1.

Ebell MH. WHO downgrades status of oseltamivir. BMJ 2017;358:j3266. [Ref.ID 101981]

2.

Zaman MJ. Cost saving is nothing to be proud of. BMJ 2017;358:j3428. [Ref.ID 101978]

3.

Anónimo. More doctors disclose payments from drug companies . BMJ 2017;358:30 de junio. [Ref.ID 101667]

4.

Larkin I, Ang D, Steinhart J, Chao M, Patterson M, Sah S, Wu T, Schoen-baum M, Hutchins D, Brennan T, Loewen-stein G. Association between academic medical center pharmaceutical detailing policies and physician prescribing. JAMA 2017;317:1785-95. [Ref.ID 101559]

5.

Anónimo. Trump takes a conciliatory tone in meeting with pharmaceutical executives. DIA Daily 2017:1. [Ref.ID 101384]

6.

Anónimo. Markets react as investors try to gauge impact of Trump’s election on healthcare sector. DIA Daily 2016:1. [Ref.ID 100916]

7.

Middleton J, McGrail S, Stringer K. Drug related deaths in England and Wales. BMJ 2016;355:i5259. [Ref.ID 100851]

8.

Sheldon T. Saving antibiotics for when they are really needed: the Dutch example. BMJ 2016;354:i4192. [Ref.ID 100707]

9.

Anónimo. Access to medicines—the status quo is no longer an option. Lancet 2016;388:1250. [Ref.ID 100699]

10.

Anónimo. UN panel questions free market approach to R&D for medicines. DIA Daily 2016:1. [Ref.ID 100664]

11.

Crow D. Poorer countries need rapid access to generic drugs, UN says. Financial Times 2016:1. [Ref.ID 100663]

12.

Anónimo. Pfizer CEO criticizes Clinton prescription drug plan as step towards single-payer. DIA Daily 2016:5. [Ref.ID 100654]

13.

Kesselheim AS, Avorn J, Sarpatwari A. The high cost of prescription drugs in the United States: origins and prospects for reform. JAMA 2016;316:858-71. [Ref.ID 100589]

14.

Anónimo. Cancer drug companies slashing prices following closure of NHS’ Cancer Drugs Fund. DIA Daily 2016:1. [Ref.ID 100585]

15.

Johansen ME, Richardson C. Estimation of potential savings through therapeutic substitution. JAMA Intern Med 2016;176:769-75. [Ref.ID 100398]

16.

Garattini S. The European Medicines Agency is still too close to industry. BMJ 2016;353:i2412. [Ref.ID 100360]

17.

Alpern JD, Song J, Stauffer WM. Essential medicines in the United States - Why access is diminishing. N Engl J Med 2016;374:1904-7. [Ref.ID 100324]

18.

Hawkes N. Speeding up access to new drugs threatens evidence based medicine, says health economist. BMJ 2016;352:i263. [Ref.ID 99981]

19.

Laporte JR. Fifty years of pharmacovigilance - Medicines safety and public health. Pharmacoepidemiol Drug Saf 2016;25:725-32. [Ref.ID 99974]

20.

Dyer O. US government is funding fewer trials as number of industry sponsored trials grows. BMJ 2015;351:h6893. [Ref.ID 99763]